Date Mailed: Sheet 1 of 7 Docket Number: 050321-1040 Application Number: 09/332,759 ON DISCLOSURE STATEMENT Applicant:: Underbrink, et al. AN APPLICATION JUN 0 7 2001 Group Art Unit:: 3661 Filing Date: April 18, 2000

Cass Surcass Filing Date NAME Cass Surcass Filing Date if Appropriate Appropriate	TER.	ator	<i></i>		U.S. PATENT DOCUMENT	rs ·		
FH M 3,604,911 9/14/71 Schmitt 235 181 FM 3,975,628 8/17/76 Graves et al. 250 199 FH M 4,426,712 1/17/84 Gorski-Popiel 375 96 FH M 4,445,118 4/24/84 Taylor et al. 343 357 FH M 4,578,628 3/25/86 Hurd 343 357 FH M 4,667,203 5/19/87 Counselman, III 342 357 FH M 4,701,934 10/20/87 Jasper 375 1 FH M 4,701,934 10/20/87 Jasper 375 1 FH M 4,785,463 11/15/88 Janc et al. 375 1 FH M 4,809,005 2/28/89 Counselman, III 342 352 FH M 4,809,005 2/28/89 Counselman, III 342 352 FH M 4,809,005 12/28/89 Counselman, III 342 352 FH M 4,809,003 12/26/89 Ando et al. 364 457 FH M 4,809,003 12/26/89 Ando et al. 364 457 FH M 4,894,662 1/16/90 Counselman 342 357 70/3600 MAIL RI FH M 4,894,842 1/16/90 Broekhoven et al: 375 1 FH M 4,998,111 3/5/91 Ma et al. 320 23 FH M 4,998,111 3/5/91 Figbie 364 574 FH M 5,018,088 5/21/91 Higbie 364 574 FH M 5,043,736 8/27/91 Darnell et al. 342 357 FH M 5,108,334 4/28/92 Eschenbach et al. 455 314 FH M 5,118,042 9/15/92 Nakazoe 307 65 FH M 5,153,591 10/6/92 Clark 341 51 FH M 5,179,724 1/12/93 Lindoff 455 76	4	ELAMINER INITIAL	DOCUMENT NO.	DATE	·		SUBCLASS	FILING DATE IF
FHM 4,426,712 1/17/84 Gorski-Popiel 375 96 FHM 4,445,118 4/24/84 Taylor et al. 343 357 FHM 4,463,357 7/31/84 MacDoran 343 460 FHM 4,578,678 3/25/86 Hurd 343 357 FHM 4,667,203 5/19/87 Counselman, III 342 357 FHM 4,701,934 10/20/87 Jasper 375 1 FHM 4,754,465 6/28/88 Trimble 375 1 FHM 4,785,463 11/15/88 Janc et al. 375 1 FHM 4,809,005 2/28/89 Counselman, III 342 352 FHM 4,809,005 2/28/89 Counselman, III 342 352 FHM 4,809,233 12/26/89 Ando et al. 364 457 FHM 4,894,662 1/16/90 Counselman 342 357 FHM 4,894,842 1/16/90 Broekhoven et al. 375 1 FHM 4,992,720 2/12/91 Hata 320 23 FHM 4,998,111 3/5/91 Ma et al. 342 352 FHM 5,018,088 5/21/91 Higbie 364 574 FHM 5,036,329 7/30/91 Ando 342 357 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,149,042 9/15/92 Nakazoe 307 655 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76	GAT		3,604,911	9/14/71	Schmitt	235	181	
FHM 4,426,712 1/17/84 Gorski-Popiel 375 96 FHM 4,445,118 4/24/84 Taylor et al. 343 357 FHM 4,63,357 7/31/84 MacDoran 343 460 FHM 4,578,678 3/25/86 Hurd 343 357 FHM 4,667,203 5/19/87 Counselman, III 342 357 FHM 4,701,934 10/20/87 Jasper 375 1 FHM 4,754,465 6/28/88 Trimble 375 1 FHM 4,809,005 2/28/89 Counselman, III 342 352 FHM 4,809,005 2/28/89 Counselman, III 342 352 FHM 4,809,033 12/26/89 Ando et al. 364 457 FHM 4,894,662 1/16/90 Counselman 342 357 70 3600 MAIL R FHM 4,894,842 1/16/90 Broekhoven et al: 375 1 FHM 4,992,720 2/12/91 Hata 320 23 FHM 4,998,111 3/5/91 Ma et al. 342 352 FHM 5,018,088 5/21/91 Higbie 364 574 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,149,042 9/15/92 Nakazoe 307 65 FHM 5,148,042 9/15/92 Nakazoe 307 65 FHM 5,149,724 1/12/93 Lindoff 455 76	0// 9	FMM	3,975,628	8/17/76	Graves et al.	250	199	• • •
FHM 4,463,357 7/31/84 MacDoran 343 460 FHM 4,578,678 3/25/86 Hurd 343 357 FHM 4,667,203 5/19/87 Counselman, III 342 357 FHM 4,701,934 10/20/87 Jasper 375 1 FHM 4,754,465 6/28/88 Trimble 375 1 FHM 4,785,463 11/15/88 Janc et al. 375 1 FHM 4,809,005 2/28/89 Counselman, III 342 352 FHM 4,821,294 4/11/89 Thomas Jr. 375 96 FHM 4,890,233 12/26/89 Ando et al. 364 457 FHM 4,890,233 12/26/89 Ando et al. 364 457 FHM 4,894,662 1/16/90 Counselman 342 357 FHM 4,894,842 1/16/90 Brockhoven et al. 375 1 FHM 4,992,720 2/12/91 Hata 320 23 FHM 4,998,111 3/5/91 Ma et al. 342 352 FHM 5,014,066 5/7/91 Counselman, III 342 352 FHM 5,014,066 5/7/91 Counselman, III 342 352 FHM 5,018,088 5/21/91 Higbie 364 574 FHM 5,036,329 7/30/91 Ando 342 357 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76	1		4,426,712	1/17/84	Gorski-Popiel	375	96	
FHM 4,578,678 3/25/86 Hurd 343 357 FHM 4,667,203 5/19/87 Counselman, III 342 357 FHM 4,701,934 10/20/87 Jasper 375 1 FHM 4,754,465 6/28/88 Trimble 375 1 FHM 4,785,463 11/15/88 Janc et al. 375 1 FHM 4,809,005 2/28/89 Counselman, III 342 352 FHM 4,821,294 4/11/89 Thomas Jr. 375 96 FHM 4,890,233 12/26/89 Ando et al. 364 457 FHM 4,894,662 1/16/90 Counselman 342 357 MO 3600 MAIL RO FHM 4,894,842 1/16/90 Broekhoven et al. 375 1 FHM 4,992,720 2/12/91 Hata 320 23 FHM 4,998,111 3/5/91 Ma et al. 342 352 FHM 5,014,066 5/7/91 Counselman, III 342 352 FHM 5,018,088 5/21/91 Higbie 364 574 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,148,042 9/15/92 Nakazoe 307 65 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76		FHM	4,445,118	4/24/84	Taylor et al.	343	357	
FHM 4,667,203 5/19/87 Counselman, III 342 357 FHM 4,701,934 10/20/87 Jasper 375 1 FHM 4,754,465 6/28/88 Trimble 375 1 FHM 4,785,463 11/15/88 Janc et al. 375 1 FHM 4,809,005 2/28/89 Counselman, III 342 352 FHM 4,821,294 4/11/89 Thomas Jr. 375 96 JUN 112/10 FHM 4,890,233 12/26/89 Ando et al. 364 457 FHM 4,894,662 1/16/90 Counselman 342 357 70/3600 MAIL R FHM 4,894,842 1/16/90 Brockhoven et al: 375 1 FHM 4,992,720 2/12/91 Hata 320 23 FHM 4,998,111 3/5/91 Ma et al. 342 352 FHM 5,014,066 5/7/91 Counselman, III 342 352 FHM 5,018,088 5/21/91 Higbie 364 574 FHM 5,036,329 7/30/91 Ando 342 357 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,148,042 9/15/92 Nakazoe 307 65 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76		FHM	4,463,357	7/31/84	MacDoran ·	343	460	
FHM 4,701,934 10/20/87 Jasper 375 1 FHM 4,754,465 6/28/88 Trimble 375 1 FHM 4,785,463 11/15/88 Janc et al. 375 1 FHM 4,809,005 2/28/89 Counselman, III 342 352 FHM 4,809,233 12/26/89 Ando et al. 364 457 FHM 4,890,233 12/26/89 Ando et al. 364 457 FHM 4,894,662 1/16/90 Counselman 342 357 FHM 4,894,842 1/16/90 Brockhoven et al. 375 1 FHM 4,992,720 2/12/91 Hata 320 23 FHM 4,998,111 3/5/91 Ma et al. 342 352 FHM 5,014,066 5/7/91 Counselman, III 342 352 FHM 5,018,088 5/21/91 Higbie 364 574 FHM 5,036,329 7/30/91 Ando 342 357 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 345 314 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76		FHM	4,578,678	3/25/86	Hurd	343	357	
### ### ##############################		FHM	4,667,203	5/19/87	Counselman, III	342	357	
### HAM		FHM	4,701,934	10/20/87	Jasper	375	1	
FHM 4,809,005 2/28/89 Counselman, III 342 352 FHM 4,821,294 4/11/89 Thomas Jr. 375 96 JUN 11 200 FHM 4,890,233 12/26/89 Ando et al. 364 457 FHM 4,894,662 1/16/90 Counselman 342 357 7/0 3600 MAIL RO FHM 4,894,842 1/16/90 Broekhoven et al. 375 1 FHM 4,992,720 2/12/91 Hata 320 23 FHM 4,998,111 3/5/91 Ma et al. 342 352 FHM 5,014,066 5/7/91 Counselman, III 342 352 FHM 5,018,088 5/21/91 Higbie 364 574 FHM 5,036,329 7/30/91 Ando 342 357 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,148,042 9/15/92 Nakazoe 307 65 FHM	,	FHM	4,754,465	6/28/88	Trimble	375	. 1	
FHM		FHM	4,785,463	11/15/88	Janc et al.	375	1	RECEIVED
FHM 4,890,233 12/26/89 Ando et al. 364 457 FHM 4,894,662 1/16/90 Counselman 342 357 760 3600 MAIL ROWS FHM 4,894,842 1/16/90 Broekhoven et al. 375 1 FHM 4,992,720 2/12/91 Hata 320 23 FHM 4,998,111 3/5/91 Ma et al. 342 352 FHM 5,014,066 5/7/91 Counselman, III 342 352 FHM 5,018,088 5/21/91 Higbie 364 574 FHM 5,036,329 7/30/91 Ando 342 357 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,148,042 9/15/92 Nakazoe 307 65 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76		FHM	4,809,005	2/28/89	Counselman, III	342	352	- in-Country - C
FHM 4,890,233 12/26/89 Ando et al. 364 457 FHM 4,894,662 1/16/90 Counselman 342 357 FHM 4,894,842 1/16/90 Broekhoven et al: 375 1 FHM 4,992,720 2/12/91 Hata 320 23 FHM 4,998,111 3/5/91 Ma et al. 342 352 FHM 5,014,066 5/7/91 Counselman, III 342 352 FHM 5,018,088 5/21/91 Higbie 364 574 FHM 5,036,329 7/30/91 Ando 342 357 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76		FRM	4,821,294	4/11/89	Thomas Jr.	375	96	.IIN 112001
FHM 4,894,842 1/16/90 Broekhoven et al. 375 1 FHM 4,992,720 2/12/91 Hata 320 23 FHM 4,998,111 3/5/91 Ma et al. 342 352 FHM 5,014,066 5/7/91 Counselman, III 342 352 FHM 5,018,088 5/21/91 Higbie 364 574 FHM 5,036,329 7/30/91 Ando 342 357 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,148,042 9/15/92 Nakazoe 307 65 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76		FHM	4,890,233	12/26/89	Ando et al.	364	457	<u> </u>
FHM 4,894,842 1/16/90 Broekhoven et al. 375 1 FHM 4,992,720 2/12/91 Hata 320 23 FHM 4,998,111 3/5/91 Ma et al. 342 352 FHM 5,014,066 5/7/91 Counselman, III 342 352 FHM 5,018,088 5/21/91 Higbie 364 574 FHM 5,036,329 7/30/91 Ando 342 357 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,148,042 9/15/92 Nakazoe 307 65 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76		FHM	4,894,662	1/16/90	Counselman	342	357	TO 3600 MAIL ROOM
FHM 4,998,111 3/5/91 Ma et al. 342 352 FHM 5,014,066 5/7/91 Counselman, III 342 352 FHM 5,018,088 5/21/91 Higbie 364 574 FHM 5,036,329 7/30/91 Ando 342 357 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,148,042 9/15/92 Nakazoe 307 65 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76		FHM	4,894,842	1/16/90	Broekhoven et al:	. 375	-1	
FHM 5,014,066 5/7/91 Counselman, III 342 352 FHM 5,018,088 5/21/91 Higbie 364 574 FHM 5,036,329 7/30/91 Ando 342 357 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,148,042 9/15/92 Nakazoe 307 65 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76		FAM	4,992,720	2/12/91	Hata	320	23	
FHM 5,018,088 5/21/91 Higbie 364 574 FHM 5,036,329 7/30/91 Ando 342 357 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,148,042 9/15/92 Nakazoe 307 65 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76	.	FHM	4,998,111	3/5/91	Ma et al.	-342	352	•
FHM 5,036,329 7/30/91 Ando 342 357 FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,148,042 9/15/92 Nakazoe 307 65 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76		FHM	5,014,066	5/7/91	Counselman, III	342	352	
FHM 5,043,736 8/27/91 Darnell et al. 342 357 FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,148,042 9/15/92 Nakazoe 307 65 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76		FHM	5,018,088	5/21/91	Higbie	364	574	
FHM 5,108,334 4/28/92 Eschenbach et al. 455 314 FHM 5,148,042 9/15/92 Nakazoe 307 65 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76		FAM	5,036,329	7/30/91	Ando	. 342	· 357	*
FHM 5,148,042 9/15/92 Nakazoe 307 65 FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76		FHM	5,043,736.	8/27/91		342	357	
FHM 5,153,591 10/6/92 Clark 341 51 FHM 5,179,724 1/12/93 Lindoff 455 76		PHM	5,108,334	4/28/92	Eschenbach et al.	455	314.	
FHM 5,179,724 1/12/93 Lindoff 455 76		FHM	5,148,042		Nakazoe	307	65	
1 NFC		FHM	5,153,591	10/6/92	Clark	341	51	
5 202 829 4/13/93 Cojor 344 449		FHM	5,179 <i>,</i> 724	1/12/93	Lindoff	455	76	
		FHM	5,202,829	4/13/93	Geier '-	364	449	
FHM 5,225,842 7/6/93 Brown et al. 342 357		FHM			Brown et al.	342	357	
5,253,268 10/12/93 Omura et al. 375 1		FAM	5,253,268	10/12/93	Omura et al.	. 375	1	
5,276,765 1/4/94 Fremman et al. 395 2	1	FHM	5,276,765	1/4/94	Fremman et al.	395	2	
FHM 5,293,170 3/8/94 Lorenz et al. 376 309	GAJ	FHM	5,293,170	3/8/94	Lorenz et al.	376	309	·

-28-02 EXAMINER: DATE CONSIDERED: EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. 314105

G: ALTHUL - Jean Slaude
*Substitute Disclosure Statement Form (PTO 1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Sheet 2 of 7

Form 1449*			Docket Number: 050321-1040	Application	Number: 09	1552759 10/792		
LINFERMATION DISCLOSURE STATEMENT			Applicant:: Underbrink, et al.					
S/IN	AN APPLICATION	l 	Filing Date: April 18, 2000	Стоир Ал	Group Art Unit:: 3661			
N 0 7 2001	5,293,398	3/8/94	Hamao et al.	375	1			
FH/					224	· · · · · · · · · · · · · · · · · · ·		
FHMS	5,297,097	3/22/94	Etoh et al.	365	226			
ADDAMA	5,311,195	5/10/94	Mathis et al.	342	357			
FHM	5,323,164	6/21/94	Endo	342	357			
FHM	5,343,209	8/30/94	Sennott et al.	342	357	·		
FMM	5,345,244	9/6/94	Gildea et al.	342	. 357			
FHM	5,347,536	9/13/94	Meehan	375	1			
FAM	5,352,970	10/4/94	Armstrong II	320	39	: .		
FHM	5,363,030	11/8/94	Ford et al.	320	.13			
FHM	5,378,155	1/3/95	Eldridge	434	11			
F4M	5,379,224	1/3/95	Brown et al.	364	449			
FHM	5,396,515	3/7/95	Dixon et al.	375	208	RECEIVE		
FHM	5,402,346	3/28/95	Lion et al.	364	436			
FHM	5,402,347	3/28/95	McBurney et al.	364	443	JUN 11 2001		
FHM	5,410,747	4/25/95	Ohmagari et al.	455	118			
FAM	5,416,712	5/16/95	Geier et al.	364	450	TO 3500 MAIL 1		
FHM	5,418,818	5/23/95	Marchetto et al.	375	264	· ·		
FIM	5,420,593	5/30/95	Niles	342	357			
FXM	5,440,313	8/8/95	Osterdock et al.	342	352			
EUM	5,450,344	9/12/95	Woo et al.	364	449			
FUM	5,498,239	3/12/96	Galel et al.	604	95			
FHM	5,504,684	4/2/96	Lau et al.	364	443			
FHM	5,546,445	8/13/96	Dennison et al.	379	60			
FHM	5,548,613	8/20/96	Kahu et al.	375	208			
FAM	5,550,811	8/27/96	Kahu et al.	370	18			
FHM	5,568,473	10/22/96	Hemmati	370	18			
FHM	5,577,023	11/19/96	Marum et al.	370	16			
FRM	5,577,025	11/19/00	Skinner et al.	370	22			
FHM	5,592,173	1/7/97	Lau et al.	342	357			
FILM	5,594,453	1/14/97	Rodal et al.	342	357			
FHM	5,608,722	3/4/97	Miller	370	320			
FHM	5,623,485	4/22/97	Bi	370	209			

EXAMINER: The	FM GAJ	DATE CONSIDERED:		1.			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.							
Composition 2 and not considered. The note copy of this form for next communication to the Applicant.							

Sheet 3 of 7

	Form 1449°			Docket Number: 050321-1040	Applica	tion Number: 09	1552759 10/792	14 3
6	A PRINTION DISCLOSURE STATEMENT			Applicam:: Underbrink, et al.				
	N AN APPLICATION			Filing Date: April 18, 2000	Group A	Group Art Unit:: 3661		
*11	0 7 2001		·					•
Jų	" FAMS	<i>I</i>	4/29/97	Loomis et al.	379	. 58		
i	FHMO	5,640,429	6/17/97	Michaels et al.	375	340		
\geq 1	A STATE OF THE STA	5,640,431	6/17/97	Bruckert et al.	375	344		
Ì	FHM	5,642,377	6/24/97	Chung et al.	375	200		
Ì	FHM	5,644,591	7/1/97	Sutton	375	200		
	FHM	5,649,000	7/15/97	Lee et al.	455	436		
	FAM	5,650,792	7/22/97	Moore et al.	343	725		
Ì	FHM	5,654,718	8/5/97	Beason et al.	342	357		
	FHM	5,663,734	9/2/97	Krasner	342	357	MECEIVE JUN 1120	U.
	FHM	5,663,735	9/2/97	Eshenbach	342	357	ME	•
	CHM	5,689,814	11/18/97	Hagisawa et al.	455	69	11 1 1 201 MIN	01
Ī	FHM	5,722,061	2/24/98	Hutchison IV et al.	455	245.1		: 001
	FAM	5,734,674	3/31/98	Fenton et al.	375	207	703600 MAIL	Boon
	FHM	5,734,966	3/31/98	Farrer et al.	455	63	10.30	
	FHM	5,737,329	4/7/98	Horiguchi	370	342		
	FHM	5,739,596	4/14/98	Takizawa et al.	307	66		
	FMM	5,749,067	5/5/98	Barrett'	704	233		
	FHM	5,781,156	7/14/98	Krasner	342	357		
ſ	FAM	5,784,695	7/21/98	Upton et al.	455	442		
	FAM	5,786,789	7/28/98	Janky	342	357		
	FIM	5,812,087	9/22/98	Krasner	342	357		
ſ	FHM	5,825,327	10/20/98	Krasner	342	357		
	FHM	5,828,694	10/27/98	Schipper	375	208	-	
	FHM	5,831,574	11/3/98	Krasner	342	357		
	FHM	5,832,021	11/3/98	Kondo	375	200		
	FHM	5,841,396	11/24/98	Krasner	342	357		
ſ	FHM	5,845,203	12/1/98	LaDue	455	414		
	FHM	5,854,605	12/29/98	Gildea	342	357		•
	Fun	5,862,465	1/19/99	Ou ,	455	234.1		
	FHM	5,867,535	2/2/99	Phillips et al.	375	. 295		
	FWL	5,867,795	2/2/99	'Novis et al.	455	566		
7	FHM	5,872,540	2/16/99	Casabona et al.	342	. 362		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

OBSTERN TRANSITION TRANSITIONS

*Substitute Disclosure Statement Form (PTO 1449)

3/4/05
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Sheet 4 of 7

[.	GNE GATION	. TO SOURE S	TATEMENT	Docket Number: 050321-1040 Applicant:: Underbrink, et al.	Applicati	on Number: 09/5	52.75 9 10/792	
	N AN APPLICATION					Group Art Unit:: 3661		
L	IIIN 0 7 2001			1 tang 5 a.c. 1410 10, 2000	Olivep 11	11 0.00.		
	FHM &	5,874,914	2/23/99	Krasner	342	357		7
(FIME	5,877,724	3/2/99	Davis	342	357	· · · · · · · · · · · · · · · · · · ·	1
9	智料	5,877,725	3/2/99	Kalafus	342	357		1
1	FHM	5,881,371	3/9/99	Reynolds	455	83		1
ľ	FHM	5,883,594	3/16/99	Lau	342	357		1
ſ	FHM	5,884,214	3/16/99	Krasner	701	207		
T	FHM	5,889,474	3/30/99	LaDue	340	825.49	·····	1
ſ	FHM	5,903,654	5/11/99	Milton et al.	380	49		
ľ	FHM	5,907,809	5/25/99	Molnar et al.	455	456		1
ſ	FHM	5,909,640	6/1/99	Farrer et al.	455	63		1
ľ	FHM	5,917,444	6/29/99	Loomis et al.	342	357	·····	
	FAM	5,917,829	6/29/99	Hertz et al.	370	479		1
	FAM	5,920,283	7/6/99	Shaheen et al.	. 342	357	0511	=
F	FHM	5,923,703	7/13/99	Pon et al.	375	209	RECEN	١
ŀ	FHM	5,924,024	7/13/99	Ikeda et al.	455	. 313	JUN 11	innt
r	FHM	5,926,131	7/20/99	Sakumoto et al.	342	357		ł
	FHM	5,936,572	8/10/99	Loomis et al.	342.	357	<u> 10 3€0ō w</u> y	IL R
	FHM	5,943,363	8/24/99	Hanson et al.	375	206	10 3606 mg]
ľ	FHM	5,945,944	8/31/99	Krasner	342	357.06		
	FHM	5,956,328	9/21/99	Sato	370	335	٠.	1
	FHM	5,963,582	10/5/99	Stansell, Jr.	375	200 .	<u> </u>	1
	FHM	5,970,084	10/19/99	Honda	375	200		
	FHM	5,977,909	11/2/99	Harrison et al.	342	357.09		1
\prod	FHM	5,982,324	11/9/99	Watters et al.	342 .	357.06		1
	FAN	5,987,016	11/16/99	He	370	335		1
	FHM	5,991,309	11/23/99	Jensen et al.	370	492		1
	FHM	5,991,613	11/23/99	Euscher et al.	455	277.1	· · · · · · · · · · · · · · · · · · ·	1
	FHM	5,995,537	11/30/99	Kondo	375	208		1
	FHM	5,999,124	12/7/99	Sheynblat .	342	357.09		
	FHM	6,002,362	12/14/99	Gudat	342	357.03		
	FHM	6,002,363	12/14/99	Krasner	342	357.1		
1	FHM	6,002,709	12/14/99	Hendrickson	375	206]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. ⁴Substitute Disclosure Statement Form (PTO-1449)

DATE CONSIDERED:

EXAMINER:

BEST AVAILABLE COPY

ORIGINALLY FILED

- WELL LIFED

Date Mailed:

Sheet 5 of 7

	Form 1449*			Docket Number: 050321-1040	Applicati	on Number: 03/23	2759 10/790	
H	ONF PRENTION	DISCLOSURE ST	TATEMENT	Applicant:: Underbrink, et al.				
	AN APPLICATION		Filing Date: April 18, 2000	Gmup A	rt Unit:: 3661			
p	UIE 1 100 E	6,009,551	12/28/99	Sheynblat	714	776.		
	AND THE	6,016,119	1/18/00	Krasner	342	357.06		
Ŷ	Meine	6,023,462	2/8/00	Nieczyporowicz et al.	370	335		
	FIM	6,041,222	2/21/00	Horton et al.	455	255	•	
-	FHM	6,047,016	4/4/00	Ramberg et al.	375	200		
r	FIM	6,047,017	4/4/00	Cahn et al.	3 <i>7</i> 5	200		
\vdash	FHM	6,049,715	4/11/00	Willhoff et al.	455	436		
\mid	FHM	6,052,081	4/18/00	Krasner	342	357.02		
	FAM	6,061,018	5/9/00	Sheynblat	342	357.06	 	
	YMU!	6,064,336	5/16/00	Krasner	342	357.05		
Γ	JW43	6,064,688	5/16/00	Yanagi	375	149		
	FHM	6,075,809	6/13/00	Naruse	375	147 .		
	FHM	6,104,338	8/15/00	Krasner	342	357.06		
	FHM	6,104,340	8/15/00	Krasner	342	357.1		
	FAN	6,107,960	8/22/00	Krasner	342	357.09		
L	EHW	6,111,540	8/29/00	Krasner	342	357.1	· · · · · · · · · · · · · · · · · · ·	
L	FHM	6,131,067	10/10/00	Girerd et al.	701	213		
L	MAY	6,133,871	10/17/00	Krasner	342	357.06		
L	FHM	6,133,873	10/17/00	Krasner	342	357.12		
Ŀ	FHM	6,133,874	10/17/00	Krasner	342	357.15		
Ł	FHA	6,150,980	11/21/00	Krasner	342	357.1		
F								
L			•	RECEIVED				
L				4 1 2001			•	
F				JUN 1 1 2001				
-				TO 3600 MAIL ROD	W			
-								
\vdash							 	

*Substitute Disclosure Statement Form (PTO-1449)

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

EXAMINER:

	Form 1449*		Docket Number: 050321-1040	Applic	Application Number: 09/552,759 /0/				
TAMOGINE!	ION DISCLOSURE STAT	EMENT	Applicant:: Underbrink, et al.				-/		
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	IN AN APPLICATION Filing Date: April 18, 2000 Group Art Unit:: 3661					-			
0.7 2004									
N 0 7 2001									
PADEMARK	<u> </u>			- .					
D. O. T. D. O. T.					 	<u> </u>			
MAUER	,		•						
							•		
					-FOE	WFD			
				- 	RECE	10-			
						i			
	,				1 NUL	T 5001			
<u> </u>			COPY OF PAPERS	+	TO 3600 N	ALL ROOM	A		
			ORIGINALLY FILED		TO 3600 F	ARILITIO			
		.		_		1			
			der			 			
					 		•		
					<u> </u>	<u> </u>			
					1				
					·				
<u> </u>					 	 			
				<u> </u>	ļ				
			•			,			
							•		
-	· · · · · · · · · · · · · · · · · · ·			+	 				
			_						
l l	_								
					 	 			
						ļ			
			(1) Paris	•	1				
			• • •	1	 				
<u> </u>				_1	<u> </u>	٠			
			FOREIGN PATENTS	T		T			
EXAMINER	DOCUMENT NO. DA	ATE	COUNTRY	CLASS	SUBCLASS	TRANSLA			
INITIAL				- 	· · · · · · · · · · · · · · · · · · ·	YES	NO		
FHM	WO 92/13392				†				
FHW	WO 00/19644			 					
Phw	EP 0511741 A1				 	<u> </u>			
1-HM	EP 0511741 B1			 	 	· ·			
EHM	EP 0639901 A2			1	<u> </u>		<u> </u>		
FHM	EP 0639901 A3			1	 _	 			
FHM	JP 08/065205 A			+=	 	ļ	<u></u>		
	JP 08/065205A		a mental and a second of the s	<u></u>	<u> </u>				

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

*Substitute Disclosure Statement Form (PTO 1449)

SIRF

GIARTHUR - JEANG/AUDE

COPY OF PAPERS ORIGINALLY FILED

MO THE	10-TED	NGLAUDE
OHI LATY	(K-JEHI	NO MODE

DATE CONSIDERED:

-28-02

3/4/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

EXAMINER: